CD33 and acute myeloid leukemia: Also, gemtuzumab-ozogamicin, an antibody–drug conjugate targeting CD33 [28,162] to add to traditional ICT, allowed survival benefits that appear limited to patients with favorable-risk CBF-AML [28].